Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 136 AL 150

Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review

Yuksel M, Tacal O.

Eur J Pharmacol. 2019 Aug 5;856:172415. doi: 10.1016/j.ejphar.2019.172415. Epub 2019 May 24.

[Drug treatment of Alzheimer's dementia : Status quo and perspectives]

Müller P, Fendt M, Müller NG.

Internist (Berl). 2019 Jul;60(7):761-768. doi: 10.1007/s00108-019-0625-4.

Alzheimer's disease: future drug development and the blood-brain barrier

Pardridge WM.

Expert Opin Investig Drugs. 2019 Jul;28(7):569-572. doi: 10.1080/13543784.2019.1627325. Epub 2019 Jun 4.

Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Hampel H, Lista S, Mango D, Nisticò R, Perry G, Avila J, Hernandez F, Geerts H, Vergallo A; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2019;69(3):615-629. doi: 10.3233/JAD-190197.

Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga S, Fujishiro H, Takechi H.

J Alzheimers Dis. 2019;69(4):1031-1039. doi: 10.3233/JAD-190256.

Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches

González JF, Alcántara AR, Doadrio AL, Sánchez-Montero JM.

Expert Opin Drug Discov. 2019 Sep;14(9):879-891. doi: 10.1080/17460441.2019.1623201. Epub 2019 Jun 5.

Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease

Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctôt KL.

Am J Geriatr Psychiatry. 2019 Nov;27(11):1161-1173. doi: 10.1016/j.jagp.2019.05.002. Epub 2019 May 8.

Contribution of astrocytes to metabolic dysfunction in the Alzheimer's disease brain

Zulfiqar S, Garg P, Nieweg K.

Biol Chem. 2019 Aug 27;400(9):1113-1127. doi: 10.1515/hsz-2019-0140.

Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?

Willbold D, Kutzsche J.

Molecules. 2019 Jun 15;24(12):2237. doi: 10.3390/molecules24122237.

Dysfunction of mitochondria: Implications for Alzheimer's disease

Albensi BC.

Int Rev Neurobiol. 2019;145:13-27. doi: 10.1016/bs.irn.2019.03.001. Epub 2019 Mar 26.

Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology

Hossain MF, Uddin MS, Uddin GMS, Sumsuzzman DM, Islam MS, Barreto GE, Mathew B, Ashraf GM.

Mol Neurobiol. 2019 Dec;56(12):8255-8276. doi: 10.1007/s12035-019-01660-3. Epub 2019 Jun 17.

Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML.

Curr Top Med Chem. 2019;19(19):1694-1711. doi: 10.2174/1568026619666190619115735.

The overlap between epilepsy and Alzheimer's disease and the consequences for treatment

Powell G, Ziso B, Larner AJ.

Expert Rev Neurother. 2019 Jul;19(7):653-661. doi: 10.1080/14737175.2019.1629289. Epub 2019 Jun 26.

Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies

Esmieu C, Guettas D, Conte-Daban A, Sabater L, Faller P, Hureau C.

Inorg Chem. 2019 Oct 21;58(20):13509-13527. doi: 10.1021/acs.inorgchem.9b00995. Epub 2019 Jun 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias